Recovery of drug-resistant influenza A virus during therapeutic use of rimantadine.
about
Amantadine and rimantadine for influenza A in children and the elderlyAmantadine and rimantadine for influenza A in children and the elderlyAmantadine and rimantadine for influenza A in children and the elderlyAmantadine and rimantadine for influenza A in adultsAmantadine and rimantadine for preventing and treating influenza A in adultsAntiviral drugs for viruses other than human immunodeficiency virusGeneration and characterization of a mutant of influenza A virus selected with the neuraminidase inhibitor BCX-140.The treatment of influenza with antiviral drugsPandemic flu: clinical management of patients with an influenza-like illness during an influenza pandemic. Provisional guidelines from the British Infection Society, British Thoracic Society, and Health Protection Agency in collaboration with the DeLarge-scale sequence analysis of M gene of influenza A viruses from different species: mechanisms for emergence and spread of amantadine resistance.Estimating effect of antiviral drug use during pandemic (H1N1) 2009 outbreak, United StatesReassortment and mutations associated with emergence and spread of oseltamivir-resistant seasonal influenza A/H1N1 viruses in 2005-2009.Developing new antiviral agents for influenza treatment: what does the future hold?Aminoadamantanes with persistent in vitro efficacy against H1N1 (2009) influenza AInfluenza virus neuraminidase: structure, antibodies, and inhibitors.Influenza in the intensive care unit.Development of antivirals against influenza.Influenza and respiratory syncytial virus in the elderly.Impact of influenza treatment with oseltamivir on health, sleep and daily activities of otherwise healthy adults and adolescents.Isolation of amantadine-resistant influenza a viruses (H3N2) from patients following administration of amantadine in JapanDetection of amantadine-resistant influenza A virus strains in nursing homes by PCR-restriction fragment length polymorphism analysis with nasopharyngeal swabs.In vitro and in vivo activities of anti-influenza virus compound T-705.Oral administration of cyclopentane neuraminidase inhibitors protects ferrets against influenza virus infection.Frequency of amantadine-resistant influenza A viruses during two seasons featuring cocirculation of H1N1 and H3N2.Occurrence of mixed populations of influenza A viruses that can be maintained through transmission in a single host and potential for reassortment.Generation and characterization of variants of NWS/G70C influenza virus after in vitro passage in 4-amino-Neu5Ac2en and 4-guanidino-Neu5Ac2en.Inhibition of influenza virus replication by adlay tea.Rimantadine: a clinical perspective.Incidence of amantadine-resistant influenza A viruses in sentinel surveillance sites and nursing homes in Niigata, Japan.Reintroduction of influenza A to a nursing building.In vitro and in vivo activities of T-705 and oseltamivir against influenza virus.Emergence and transmission of amantadine-resistant influenza A in a nursing home.Anti-influenza therapy: the emerging challenge of resistance
P2860
Q24187883-C9F358D9-BAAF-41F7-945A-D223448BD54BQ24203853-8257B09D-8E66-4C3A-B9CD-6B6FFC91F7F3Q24242639-45E09E4D-DE45-4ABF-9C38-9392A33AAE0AQ24246351-25092B6D-ACEE-4EC8-97FE-C0845640DB8CQ24246830-408DF540-328A-44A3-86E7-CFFE63B4B1E1Q24635330-8687481E-773C-4D54-B3FE-F91835884EB8Q28379467-CCDE9658-8808-4950-AD47-C32912ADB374Q30332377-D03A23B9-3D2C-4919-A427-524C514BB0C7Q30359034-DF71D093-96D3-4036-B328-7306BBBC72E0Q30379476-A2500CD2-7839-4372-AAC4-8FAC17AB3030Q30406680-3656867D-9E13-46DD-8DD9-2F5596C9F440Q33869689-467148DE-28A9-4FA9-B9FF-0BA6186D9A41Q34015113-368ACEBD-F295-468B-9502-D3F4A124D1DDQ34023430-82944305-F0E7-4253-B9D4-0544135D717FQ34318113-00088D64-1324-4348-8E0F-4C6DE6BD6CABQ35800321-BBED0B67-10D5-467F-B2A4-4D04250338FCQ36181153-FD1BE6E5-30CC-47D6-A6EC-4F8F1D7480A0Q37103929-C45023D2-D847-4F66-B1FA-A4D9835F5D3DQ39342330-5CDBAE46-CAEA-47B6-A590-882C034E1846Q39464368-4A7D4677-B642-458D-A414-B41A8951FB58Q39626221-770A92D3-760F-4DE9-9EA2-0EE25CD4918AQ39651429-09772A08-2ED6-408B-88AE-EB44C59BF256Q39651456-A91DA71E-A0EF-4BC2-A14D-2CC145B56CDDQ39751284-0699E967-205C-4220-B392-055245F50AB3Q39770492-3264F446-9157-44DD-96E1-BAAFBDD65390Q39781147-858251C7-9A9C-49AD-B3F2-8134369E8087Q40043688-65B28386-76F5-483A-886C-A73C18EF61C4Q40441770-865E402D-0B27-4A8D-85BC-B3CC67748601Q43209459-3384BB8A-1819-4A89-8E0E-F024A898FFEDQ44173933-6B8AEE14-91BC-45E9-9A60-826EBB3454C1Q44705790-27A125C8-ABE3-4DB6-A2F8-FD03EEB988E4Q45280919-FBF11AEC-C36B-4544-A5AD-32F24FA89476Q58066873-6B791716-4987-4217-B3F8-A6586BBE5C95
P2860
Recovery of drug-resistant influenza A virus during therapeutic use of rimantadine.
description
1991 nî lūn-bûn
@nan
1991 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1991 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1991年の論文
@ja
1991年学术文章
@wuu
1991年学术文章
@zh-cn
1991年学术文章
@zh-hans
1991年学术文章
@zh-my
1991年学术文章
@zh-sg
1991年學術文章
@yue
name
Recovery of drug-resistant influenza A virus during therapeutic use of rimantadine.
@ast
Recovery of drug-resistant influenza A virus during therapeutic use of rimantadine.
@en
type
label
Recovery of drug-resistant influenza A virus during therapeutic use of rimantadine.
@ast
Recovery of drug-resistant influenza A virus during therapeutic use of rimantadine.
@en
prefLabel
Recovery of drug-resistant influenza A virus during therapeutic use of rimantadine.
@ast
Recovery of drug-resistant influenza A virus during therapeutic use of rimantadine.
@en
P2093
P2860
P356
P1476
Recovery of drug-resistant influenza A virus during therapeutic use of rimantadine.
@en
P2093
P2860
P304
P356
10.1128/AAC.35.9.1741
P407
P577
1991-09-01T00:00:00Z